The Cancer Letter

Inside information on cancer research and drug development

FDA News: Zydelig Tablets Approved In Three Blood Cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Zydelig is indicated for patients with relapsed chronic lymphocytic leukemia in combination with rituximab for whom rituximab alone would be considered appropriate therapy; as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma; and for small lymphocytic lymphoma patients who have received at least two prior systemic therapies.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Health Equity

Solving problems doctors can’t fix: How Georgetown’s medical-legal partnership saves lives by including lawyers on cancer care teams
Why every cancer center needs a Cancer LAW Project

By the end of 2022, Toni Monteiro had no fight left in her. She had been battling a rare blood cancer for three years. Her husband had just died. She was at risk of being evicted from her Washington, DC, apartment. Also, her heart was failing. “You’re really under stress,” Monteiro recalls her physician saying. ...

By Matthew Bin Han Ong
Health Equity

ACS is using an AI-powered platform in the largest-ever population study of Black women
Time and resources freed up from data management will go to outreach and access

VOICES of Black Women, the largest population study of Black women in the United States, will be the first of American Cancer Society’s large-scale population studies to be initiated using an AI-driven data management platform—promising to bring observational cancer research out of the age of Excel data files and email sharing.
By Jacquelyn Cobb
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account